Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remtolumab
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Remtolumab (ABT-122) is a novel dual-variable domain immunoglobulin (DVD-Ig™) engineered to simultaneously and selectively neutralize both tumor necrosis factor alpha (TNFα) and interleukin-17A (IL-17A). It was developed as a bispecific monoclonal antibody for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis. The drug was designed to combine the therapeutic effects of TNF inhibition with IL-17A blockade in a single molecule, aiming to improve efficacy over existing monotherapies. Clinical trials demonstrated that ABT-122 had similar safety and efficacy profiles compared to adalimumab but did not show clear superiority; development has since been discontinued for its primary indications[1][2][3][4][5].
- Other names
- Dual variable domain immunoglobulinDVD-IgDVD–Ig™
02
Targets
IL-17A (Interleukin-17A)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on remtolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remtolumab.